Clinical Pharmacology, Pharmacogenetics and Teratology
|
Faculty and staff
Section chiefs
Faculty
Collaborating faculty
Research staff
- Todd Anderson, MS
- Stacy Cossette-Ladwig, MS
- Karthika Divakaran, MS
- Katryn Eske, BS
- Nedra Johnson, RN, BSN
- Zora Jovanovic, RN, BSN
- Sevasti Koukouritaki, PhD
- Min Le, PhD
- Jeffery Shadley, PhD
- Sarah Thill, BS
- Xuejan Zang, PhD
- Tracy Zembles, PharmD
Administrative staff
- Kim Langosch
- Joan Nowak, BA
- Mary (Katie) Miller, BS
- Cathy Kortendick
|
About us
The disciplines of pharmacology and toxicology have evolved dramatically within the last 15 years in large part because of recent progress in genetics, the availability of advanced molecular tools and improved analytical chemistry techniques. Despite these advances, birth defects remain the leading cause of mortality in early childhood with the cause unknown in about 80 percent of cases. In the area of pharmaceuticals, three-quarters of all medications marketed today do not carry Food and Drug Administration approved labeling for use in neonates, infants, children and/or adolescents. An urgent need exists for expanding our fundamental knowledge of developmental toxicology and pharmacology and integrating this knowledge into risk assessment, risk management and therapeutic practice for children. In light of these needs, the goals of the research in Clinical Pharmacology, Pharmacogenetics and Teratology are to:
- Expand basic knowledge regarding developmental clinical pharmacology and toxicology.
- Effectively translate advances in the basic sciences to applied clinical medicine, particularly in the area of pharmacogenetics and toxicogenetics.
- Encourage the training of physicians and scientists to better understand inter-individual and developmental variation in human response to drugs and toxicants.
|
Recent presentations/workshops
Ronald Hines, PhD
- Annual Toxicology and Risk Assessment Conference. Developmental Changes in Human Drug Metabolizing Enzymes. 2004, Apr. 25-30; Cincinnati, Ohio.
- Annual Teratology Society Meeting. Ontogeny of Drug Metabolizing Enzymes. 2004, Jun. 26 Ð Jul. 1; Vancouver, BC, Canada.
- Annual Meeting of the Society of Toxicology. Human Hepatic Phase I Developmental Expression. 2005, Mar. 6-10; New Orleans, L.a.
- Experimental Biology. 2005, Developmental Regulation of Human Hepatic CYP2C. 2005, Apr. 2-6; San Diego, Calif.
- Experimental Biology, 2005. Pharmacogenetics of FMO1 and FMO3. 2005, Apr. 2-6; San Diego, Calif.
- Joint 2005 ISSX/JSSX Meeting. Ontogeny of Human Hepatic Drug Metabolizing Enzymes: Implications for Drug Development and Adverse Drug Reactions. 2005, Oct. 23-27; Maui, Hawaii.
- Annual Meeting of the Society of Toxicology of Canada. Developmental Expression of Phase I and Phase II Enzymes: Implications for Developmental Toxicology. 2005, Dec. 5-6; Montreal, Quebec, Canada.
- Annual Meeting of the American Association for the Advancement of Science. Ontogeny of Drug Biotransformation and Adverse Drug Reactions in Children. 2006, Feb. 16-20; St. Louis, Mo.
- Annual American Association of Pharmaceutical Scientists Meeting. Ontogeny of Drug Metabolism: Implications for Adverse Drug Reactions in Children. 2006, Oct. 29 - Nov. 2; San Antonio, Texas.
- Annual Meeting of the International Life Sciences Institute, Health and Environmental Sciences Institute. Genetic Differences in Sensitive Populations. 2007, Jan. 20-25; Cancun, Mexico.
- Randy Rose Memorial Symposium, , "Human Hepatic Cytochrome P450 Ontogeny". 2007, Mar. 14; North Carolina State University, Raleigh, N.C.
- Experimental Biology, 2007. Developmental Expression of FMO1 and FMO3: Mechanisms and Variability. 2007, Apr 28 - May 2; Washington, D.C.
- Annual Society of Toxicology Meeting. Regulatory Polymorphisms and Their Impact on Susceptibility. 2008, Mar. 16-20; Seattle, Wash.
- Tenth European ISSX Meeting. Developmental Expression of Human Hepatic Monooxygenase and Drug Metabolizing Enzymes. 2008, May 18-21; Vienna, Austria.
- 35th Meeting of the Japanese Society of Toxicology. Ontogeny of Human Hepatic Enzymes Impacting Drug and Toxicant Disposition and Response. 2008, Jun. 26-28; Tokyo, Japan.
D. Gail McCarver, MD
American Pain Society. Pharmacogenetics of Analgesia and Sedation. 2005, Mar.; Boston, Mass.
Dupont Children's Hospital and Thomas Jefferson University. Genetic and Developmental Human CYP2E1 Variation: Role in Susceptibility to Toxicants? Visiting Professor, Department of Pediatrics. 2005, Apr.; Wilmington, Del.
Children's Oncology Group Annual Meeting. Developmental Pharmacology and Environmental Toxicants. Epidemiology Symposium, 2006, Mar. 23; Milwaukee.
National Institutes of Health Sponsored Symposium on Pediatric Pharmacology. Genotype-Phenotype Studies in Pediatric Pharmacology. 2006, Apr.; Little Rock, Ark.
Health and Environmental Sciences Institute Annual Meeting. HESI Scientific Session on Sensitive Populations. Chair and Panel Discussant. 2007, Jan.; Cancun, Mexico.
The Toxicology Forum, 33rd Annual Summer Meeting. Ketamine and Neuroapoptosis: Does the Animal Data Apply to Humans? National Institutes of Health and Food and Drug Administration Panel Discussion. 2007, Jul. 8; Aspen, Colo.
Medical College of Wisconsin, Wisconsin Poison Center, Department of Pediatrics and Department of Pathology. Applying Pharmacogenetics in the Clinical Setting. 2008, Apr. 2; Milwaukee.
Christine Cronk, ScD
- Teratology Society. Potential for Misclassification in the Diagnosis of Fetal Alcohol Syndrome Due to Palpebral Fissure Length Measurement Error 2004, Jun.; Philadelphia, Pa.
- Children's Hospital of Wisconsin Grand Rounds. National Children's Study, Waukesha Vanguard Center. 2006, Jan.27; Milwaukee.
- Medical College of Wisconsin Epidemiology Seminar Series. National Children's Study, Waukesha Vanguard Center. 2006, Mar.; Milwaukee. Teratology Society. Models of Teratognenesis of Mexican American Women in Milwaukee. 2006, Jun.; Tucson, Ariz.
- Community-campus Partnerships for Health Annual Conference. Salud para Todos- "Querer es Poder!": Bridge Cultural Barriers in Milwaukee with Bilingual Chronic Care Project. 2006,May 31 -Jun. 3; Minneapolis, Minn.
- Community-campus Partnerships for Health. Saber para la Gente: Knowledge for the People. 2007, Apr. 11-14; Toronto, Ontario, Canada.
- Pediatric Academic Societies. Community Outreach and Engagement in the National Children
 s Study Vanguard Centers. 2007, May 5; Toronto, Ontario, Canada.
- Institute for Community Research: Crossroads II Conference. Community Outreach and Engagement for the National Children's Study 2007, Jun. 7-9; 2007, Hartford Conn.
- International Society for Environmental Epidemiology 19th Annual Meeting. Use of GIS in Sampling Stratification Selection for the National Children's Study Waukesha Vanguard Center. 2007, Sept.7-9; Mexico City, Mexico.
- Marquette College of Nursing. Vulnerable Populations and Community-based Participatory Research (with E. Willis). 2008, Mar.; Milwaukee.
Michael Stephens, MD, FAAP
- Annual Meeting of the North American Society of Pediatric Gastroenterology. ABC Transporter Pharmacogenetics: Impact on Thiopurine Therapy. Hepatology and Nutrition. 2006, Oct. 20.
-
Annual Meeting of the North American Society of Pediatric Gastroenterology. Pharmacogenetics of IBD Therapy. Hepatology and Nutrition. Meet the Professor Breakfast Michael C. Stephens MD and Ernest Seidman, MD. 2007, Oct. 26; Salt Lake City, Utah.
Amy Drendel, DO, MS
- Pediatric Emergency Medicine. Challenges and Controversies. Pediatric Mock Codes, 2006; Waukesha, Wis.
- Facilitator for a small group in pre-hospital pain assessment and management for children. 2006; Milwaukee.
- Pediatric Academic Society Meeting. Special Interest Group: Pediatric Emergency Medicine. 2007; Toronto, Ontario, Canada.
|
Extramural committees and activities
Ronald Hines, PhD
1994-
Editorial board, Drug Metabolism and Disposition
1998-
Editorial board, Chemico-Biological Interactions
2000-
Associate editor, Journal of Pharmacology & Experimental Therapeutics
2002-2011
Board of Trustees, International Life Sciences Institute, Health and Environmental Sciences Institute
2003-2005
International Life Sciences Institute/Risk Science Institute working group on Physiological Parameters of Early Life Stages
2003-2007
Councilor, American Society of Pharmacology and Experimental Therapeutics Executive Council
2004, 2007
International Life Sciences Institute/Health and Environmental Sciences Institute Board of Trustees Executive Committee
2004
USEPA Reproductive and Developmental Toxicology Division External Review Panel
2007-2008
Program committee, 2008 North American ISSX Meeting, San Diego, Calif.
2008
National Institutes of Child Health and Human Development Expert Panel on Pharmacology and Therapeutics
2008-2011
Councilor, Society of Toxicology Board of Councilors
D. Gail McCarver, MD
1994-
Reviewer, Drug Metabolism and Disposition
2000-
Reviewer, Alcoholism: Clinical and Experimental Research
2001-
Reviewer, Toxicology and Applied Pharmacology
2001-
Reviewer, Pharmacogenetics
2003-
Reviewer, Journal of Pharmacology and Experimental Therapeutics
2004-
Reviewer, Birth Defects Research (Part A)
2005-2008
National Toxicology Program Board of Scientific Counselors (2006-2008, chair)
2006
Session chair, American Society of Pharmacology and Experimental Therapeutics Annual Meeting. Pediatric Clinical Pharmacology: Recent Advances and Future Challenges. 2006, Apr.
Christine Cronk, ScD
2006-
Chair, National Children's Study Outreach and Engagement Team
Reviewer, Birth Defects Research Part A: Clinical and Molecular Teratology
Reviewer, Drug and Alcohol Dependence
Michael Stephens, MD, FAAP
2004
Invited reviewer, Inflammatory Bowel Diseases
2005-2007
Section editor, (Pediatric Gastroenterology), Current Treatment Options in Gastroenterology
2006
Invited reviewer, Clinical Immunology
2006-
Member, IBD Committee, North American Society of Pediatric Gastroenterology, Hepatology and Nutrition
Amy Drendel, DO, MS
2005
Reviewer, Pediatrics
2006
Reviewer, Pharmacoepidemiology and Drug Safety
2007
Abstract reviewer, Pediatric Academic Society Annual Meeting |
|
